New therapeutics from Nature: The odd case of the bacterial cytotoxic necrotizing factor 1

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Natural products may represent a rich source of new drugs. The enthusiasm toward this topic has recently been fueled by the 2015 Nobel Prize in Physiology or Medicine, awarded for the discovery of avermectin and artemisinin, natural products from Bacteria and Plantae, respectively, which have targeted one of the major global health issues, the parasitic diseases. Specifically, bacteria either living in the environment or colonizing our body may produce compounds of unexpected biomedical value with the potentiality to be employed as therapeutic drugs. In this review, the fascinating history of CNF1, a protein toxin produced by pathogenic strains of Escherichia coli, is divulged. Even if produced by bacteria responsible for a variety of diseases, CNF1 can behave as a promising benefactor to mankind. By modulating the Rho GTPases, this bacterial product plays a key role in organizing the actin cytoskeleton, enhancing synaptic plasticity and brain energy level, rescuing cognitive deficits, reducing glioma growth in experimental animals. These abilities strongly suggest the need to proceed with the studies on this odd drug in order to pave the way toward clinical trials.

Original languageEnglish
Pages (from-to)929-937
Number of pages9
JournalBiomedicine and Pharmacotherapy
Volume101
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Biological Products
Bacteria
Pharmaceutical Preparations
Nobel Prize
rho GTP-Binding Proteins
Parasitic Diseases
Neuronal Plasticity
Actin Cytoskeleton
Glioma
Therapeutics
History
Medicine
Clinical Trials
Escherichia coli
Brain
Growth
cytotoxic necrotizing factor type 1
Proteins
avermectin
artemisinine

Keywords

  • Bacterial products
  • Drug discovery
  • Energy metabolism
  • Memory
  • Neurological disorders
  • Synaptic plasticity

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{d939e82fdbf545f7a10834ca3344b6a1,
title = "New therapeutics from Nature: The odd case of the bacterial cytotoxic necrotizing factor 1",
abstract = "Natural products may represent a rich source of new drugs. The enthusiasm toward this topic has recently been fueled by the 2015 Nobel Prize in Physiology or Medicine, awarded for the discovery of avermectin and artemisinin, natural products from Bacteria and Plantae, respectively, which have targeted one of the major global health issues, the parasitic diseases. Specifically, bacteria either living in the environment or colonizing our body may produce compounds of unexpected biomedical value with the potentiality to be employed as therapeutic drugs. In this review, the fascinating history of CNF1, a protein toxin produced by pathogenic strains of Escherichia coli, is divulged. Even if produced by bacteria responsible for a variety of diseases, CNF1 can behave as a promising benefactor to mankind. By modulating the Rho GTPases, this bacterial product plays a key role in organizing the actin cytoskeleton, enhancing synaptic plasticity and brain energy level, rescuing cognitive deficits, reducing glioma growth in experimental animals. These abilities strongly suggest the need to proceed with the studies on this odd drug in order to pave the way toward clinical trials.",
keywords = "Bacterial products, Drug discovery, Energy metabolism, Memory, Neurological disorders, Synaptic plasticity",
author = "Zaira Maroccia and Stefano Loizzo and Sara Travaglione and Claudio Frank and Alessia Fabbri and Carla Fiorentini",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.biopha.2018.02.140",
language = "English",
volume = "101",
pages = "929--937",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - New therapeutics from Nature

T2 - The odd case of the bacterial cytotoxic necrotizing factor 1

AU - Maroccia, Zaira

AU - Loizzo, Stefano

AU - Travaglione, Sara

AU - Frank, Claudio

AU - Fabbri, Alessia

AU - Fiorentini, Carla

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Natural products may represent a rich source of new drugs. The enthusiasm toward this topic has recently been fueled by the 2015 Nobel Prize in Physiology or Medicine, awarded for the discovery of avermectin and artemisinin, natural products from Bacteria and Plantae, respectively, which have targeted one of the major global health issues, the parasitic diseases. Specifically, bacteria either living in the environment or colonizing our body may produce compounds of unexpected biomedical value with the potentiality to be employed as therapeutic drugs. In this review, the fascinating history of CNF1, a protein toxin produced by pathogenic strains of Escherichia coli, is divulged. Even if produced by bacteria responsible for a variety of diseases, CNF1 can behave as a promising benefactor to mankind. By modulating the Rho GTPases, this bacterial product plays a key role in organizing the actin cytoskeleton, enhancing synaptic plasticity and brain energy level, rescuing cognitive deficits, reducing glioma growth in experimental animals. These abilities strongly suggest the need to proceed with the studies on this odd drug in order to pave the way toward clinical trials.

AB - Natural products may represent a rich source of new drugs. The enthusiasm toward this topic has recently been fueled by the 2015 Nobel Prize in Physiology or Medicine, awarded for the discovery of avermectin and artemisinin, natural products from Bacteria and Plantae, respectively, which have targeted one of the major global health issues, the parasitic diseases. Specifically, bacteria either living in the environment or colonizing our body may produce compounds of unexpected biomedical value with the potentiality to be employed as therapeutic drugs. In this review, the fascinating history of CNF1, a protein toxin produced by pathogenic strains of Escherichia coli, is divulged. Even if produced by bacteria responsible for a variety of diseases, CNF1 can behave as a promising benefactor to mankind. By modulating the Rho GTPases, this bacterial product plays a key role in organizing the actin cytoskeleton, enhancing synaptic plasticity and brain energy level, rescuing cognitive deficits, reducing glioma growth in experimental animals. These abilities strongly suggest the need to proceed with the studies on this odd drug in order to pave the way toward clinical trials.

KW - Bacterial products

KW - Drug discovery

KW - Energy metabolism

KW - Memory

KW - Neurological disorders

KW - Synaptic plasticity

UR - http://www.scopus.com/inward/record.url?scp=85043455798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043455798&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2018.02.140

DO - 10.1016/j.biopha.2018.02.140

M3 - Review article

C2 - 29635902

AN - SCOPUS:85043455798

VL - 101

SP - 929

EP - 937

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

ER -